Numinous
A neural biomarker detection platform revolutionising mental health treatment.
One in five Americans are on mental health medication, yet 40% of initial psychiatric prescriptions are wrong, resulting in worse patient outcomes, wasted medication and an annual cost of more than US$100B. Numinous solves this trial and error within mental health. We use electrical brain signatures (EEG) and machine learning to predict patient response transforming patient care and ensuring correct treatment at baseline. To enable this, we have analysed over 1000 subjects’ data from multiple sources via our signal processing pipeline, improving precision compared to the current state-of-the-art. We have established partnerships with affordable EEG manufacturers, academic institutions and drug development companies in mental health.
Professor Stephen Faraone, president of the world federation of ADHD, and Michael Laskoff, founder of AbleTo and experienced mental-health entrepreneur, are among our advisors.